{"entity": "researcher", "timestamp": "2026-08-10T14:06:17.779Z", "family": "Diaz-Torne", "given": "Cesar", "initials": "C", "orcid": "0000-0001-6275-7699", "affiliations": ["Group of Inflammatory Diseases, Institute Rec. Hospital de la Santa Creu I Sant Pau, Carrer de Sant Quint\u00ed, 89, 08041, Barcelona, Spain."], "links": {"self": {"href": "https://publications.scilifelab.se/researcher/73efb37f78fa445abfffedf5637980c2.json"}, "display": {"href": "https://publications.scilifelab.se/researcher/73efb37f78fa445abfffedf5637980c2"}}, "publications": [{"entity": "publication", "iuid": "a86762f9de524cda81209022c11b0d9a", "links": {"self": {"href": "https://publications.scilifelab.se/publication/a86762f9de524cda81209022c11b0d9a.json"}, "display": {"href": "https://publications.scilifelab.se/publication/a86762f9de524cda81209022c11b0d9a"}}, "title": "Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study.", "authors": [{"family": "Murillo-Saich", "given": "Jessica D", "initials": "JD", "orcid": "0000-0002-1169-2888", "researcher": {"href": "https://publications.scilifelab.se/researcher/a684b93b3abc4e8cb1d4f3bae1cdf455.json"}}, {"family": "Diaz-Torne", "given": "Cesar", "initials": "C", "orcid": "0000-0001-6275-7699", "researcher": {"href": "https://publications.scilifelab.se/researcher/73efb37f78fa445abfffedf5637980c2.json"}}, {"family": "Ortiz", "given": "M Angeles", "initials": "MA", "orcid": "0000-0002-1574-9861", "researcher": {"href": "https://publications.scilifelab.se/researcher/243748b00db04ff3839b28ffd0e10342.json"}}, {"family": "Coras", "given": "Roxana", "initials": "R", "orcid": "0000-0001-9547-218X", "researcher": {"href": "https://publications.scilifelab.se/researcher/4b99a9f4229640fb852d6bb63ce29f76.json"}}, {"family": "Gil-Alabarse", "given": "Paulo", "initials": "P", "orcid": "0000-0002-9721-9302", "researcher": {"href": "https://publications.scilifelab.se/researcher/767596fb608b403da5a7b74588ab5208.json"}}, {"family": "Pedersen", "given": "Anders", "initials": "A", "orcid": "0000-0001-8704-5129", "researcher": {"href": "https://publications.scilifelab.se/researcher/c01eb312c2a0478da73e5f12d84658da.json"}}, {"family": "Corominas", "given": "Hector", "initials": "H", "orcid": "0000-0002-7738-6787", "researcher": {"href": "https://publications.scilifelab.se/researcher/36f3714621c8418fa018336e4f35417c.json"}}, {"family": "Vidal", "given": "Silvia", "initials": "S", "orcid": "0000-0002-3909-6682", "researcher": {"href": "https://publications.scilifelab.se/researcher/ff81c75ab3374ebf8077c87ab6f0ba77.json"}}, {"family": "Guma", "given": "Monica", "initials": "M", "orcid": "0000-0003-1951-9411", "researcher": {"href": "https://publications.scilifelab.se/researcher/6893a4ae972846e7af66871d75744030.json"}}], "type": "journal article", "published": "2021-08-16", "journal": {"title": "Metabolomics", "issn": "1573-3890", "volume": "17", "issue": "9", "pages": "74", "issn-l": "1573-3882"}, "abstract": "To study metabolic signatures can be used to identify predictive biomarkers for a patient's therapeutic response.\n\nWe hypothesized that the characterization of a patients' metabolic profile, utilizing one-dimensional nuclear magnetic resonance (1H-NMR), may predict a response to tocilizumab in patients with rheumatoid arthritis (RA).\n\n40 active RA patients meeting the 2010 ACR/EULAR classification criteria initiating treatment with tocilizumab were recruited. Clinical outcomes were determined at baseline, and after six and twelve months of treatment. EULAR response criteria at 6 and 12 months to categorize patients as responders and non-responders. Blood was collected at baseline and after six months of tocilizumab therapy. 1H-NMR was used to acquire a spectra of plasma samples. Chenomx NMR suite 8.5 was used for metabolite identification and quantification. SPSS v.27 and MetaboAnalyst 4.0 were used for statistical and pathway analysis.\n\nIsobutyrate, 3-hydroxybutyrate, lysine, phenylalanine, sn-glycero-3-phosphocholine, tryptophan and tyrosine were significantly elevated in responders at the baseline. OPLS-DA at baseline partially discriminated between RA responders and non-responders. A multivariate diagnostic model showed that concentrations of 3-hydroxybutyrate and phenylalanine improved the ability to specifically predict responders classifying 77.1% of the patients correctly. At 6 months, levels of methylamine, sn-glycero-3-phosphocholine and tryptophan tended to still be low in non-responders.\n\nThe relationship between plasma metabolic profiles and the clinical response to tocilizumab suggests that 1H-NMR may be a promising tool for RA therapy optimization. More studies are needed to determine if metabolic profiling can predict the response to biological therapies in RA patients.", "doi": "10.1007/s11306-021-01822-2", "pmid": "34402961", "labels": {"Swedish NMR Centre": "Collaborative"}, "xrefs": [{"db": "pii", "key": "10.1007/s11306-021-01822-2"}], "notes": [], "created": "2021-12-08T15:55:31.199Z", "modified": "2025-10-17T13:03:55.665Z"}]}